Chemistry:SR9011
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H31ClN4O3S |
| Molar mass | 479.04 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAα with a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ.[1] It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.[2][3][4][5][6][7]
See also
References
- ↑ "Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists". Nature 485 (7396): 62–8. March 2012. doi:10.1038/nature11030. PMID 22460951. Bibcode: 2012Natur.485...62S.
- ↑ "Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour". Nature Communications 5: 5759. December 2014. doi:10.1038/ncomms6759. PMID 25536025. Bibcode: 2014NatCo...5.5759B.
- ↑ "Circadian clock: Time for novel anticancer strategies?". Pharmacological Research 100: 288–95. October 2015. doi:10.1016/j.phrs.2015.08.008. PMID 26319800.
- ↑ "Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs". Rapid Communications in Mass Spectrometry 30 (5): 635–51. March 2016. doi:10.1002/rcm.7470. PMID 26842585. Bibcode: 2016RCMS...30..635T.
- ↑ "Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence". Nature 553 (7688): 351–355. January 2018. doi:10.1038/nature25170. PMID 29320480. Bibcode: 2018Natur.553..351S.
- ↑ "REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009". Biochemical Pharmacology 150: 1–8. April 2018. doi:10.1016/j.bcp.2018.01.009. PMID 29355503.
- ↑ "The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia". Frontiers in Immunology 11: 550145. 2020. doi:10.3389/fimmu.2020.550145. PMID 33101272.
 |  |
